| Literature DB >> 30986255 |
Harald Hegen1, Anne Zinganell1, Michael Auer1, Florian Deisenhammer1.
Abstract
BACKGROUND: The presence of ≥3 oligoclonal bands (OCB) in the cerebrospinal fluid (CSF) without corresponding bands in serum represents a definite pathological pattern, whereas the clinical significance of 1-2 CSF bands (borderline pattern) is poorly investigated.Entities:
Mesh:
Year: 2019 PMID: 30986255 PMCID: PMC6464233 DOI: 10.1371/journal.pone.0215410
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Borderline oligoclonal bands.
Borderline OCB pattern was defined as one clear CSF band (type a) or two clear CSF bands (type b) without corresponding band(s) in serum, or as weak bands in CSF that are not clearly distinguishable from artefacts (type c). Abbreviations: CSF, cerebrospinal fluid; OCB, oligoclonal bands.
Fig 2Sample flow chart.
1 OCB negative status was defined as no bands in CSF and serum, or as bands in the CSF identical to those in serum. 2 OCB positive status was defined as three or more bands in the CSF without corresponding bands in serum. 3 Borderline OCB pattern was the case when one or two clear bands were present in the CSF without corresponding band(s) in serum, or when weak bands in CSF were not clearly distinguishable from artefacts. 4 Original borderline OCB pattern could not be recovered in 35 CSF and serum sample pairs which were excluded from analysis. 5 A total of 63 patients were excluded because clinical information was either missing or insufficient for allocation to disease groups (according to Teunissen et al. Mult Scler. 2013 Nov;19(13):1802–9). 6 Patients with non-inflammatory diseases (i.e. of the NIND, SC, and no neurological disease group) require normal CSF WBC count. Therefore, a total of 10 patients of the NIND (two patients each with traumatic brain injury, stroke, CNS neoplasia, subcortical arteriosclerotic encephalopathy, polyneuropathy) and 4 of the SC group (three with vertebrogenic syndromes and one with headache associated with infection) showing a median WBC count of 6/μl were excluded. Abbreviations: CNS, central nervous system; CSF, cerebrospinal fluid; IEF, isoelectric focusing; NIND, non-inflammatory neurological disease; OCB, oligoclonal bands; SC, symptomatic control; WBC, white blood cell.
Fig 3Literature search criteria.
1 limited to 1st September 2018 2 Studies were eligible when NINDC, SC, SAS or healthy subjects (Teunissen et al. Mult Scler. 2013 Nov;19(13):1802–9) were part of study population. 3 Freedman et al. Arch Neurol. 2005 Jun;62(6):865–70; Andersson et al. J Neurol Neurosurg Psychiatry. 1994 Aug;57(8):897–902 n, number of items returned by PubMed search Abbreviations: CIS, clinically isolated syndrome; CSF, cerebrospinal fluid; IEF, isoelectric focusing; IgG, immunoglobulin G; IgM, immunoglobulin M; MS, multiple sclerosis; NINDC, non-inflammatory neurological disease controls; OCB, oligoclonal bands; SAS, spinal anesthesia subjects; SC, symptomatic controls.
Demographic and routine CSF findings according to disease groups.
| IND | NIND | PIND | SC | NND | |
|---|---|---|---|---|---|
| 55 | 89 | 36 | 52 | 21 | |
| 39.3 (16.7–75.1) | 51.7 (21.6–76.3) | 57.5 (26.8–77.0) | 36.8 (22.3–67.9) | 37.6 (22.3–57.4) | |
| 24 (43.6) | 40 (44.9) | 12 (33.3) | 35 (67.3) | 15 (71.4) | |
| 3 (0–4640) | 1 (0–1600) | 1 (0–4800) | 0 (0–250) | 0 (0–3360) | |
| 11 (0–1600) | 1 (0–3) | 1 (0–10) | 1 (0–3) | 0 (0–3) | |
| 65 (30–291) | 52 (30–93) | 81 (44–236) | 47 (24–75) | 42 (22–70) | |
| 9.4 (3.5–49.4) | 6.5 (3.3–15.4) | 12.5 (4.8–45.9) | 5.7 (3.0–10.3) | 4.7 (2.3–11.6) | |
| 0.53 (0.39–0.79) | 0.47 (0.39–0.60) | 0.54 (0.40–0.76) | 0.49 (0.38–0.61) | 0.49 (0.36–0.65) | |
| 1 (2)# | 0 | 0 | 0 | 0 |
Data are shown as median (5th– 95th percentile) unless specified otherwise. # % IgGIF according to Reiber (Reiber H. J Neurol Sci. 1994;122:189–203) and Auer & Hegen (Auer M, Hegen H et al. Eur J Neurol. 2016;23:713–721) formulae was 62% and 66%, respectively, in the single patient of the IND group. Clinical diagnosis of this patient was HIV encephalopathy.
Abbreviations: CSF, cerebrospinal fluid; HIV, human immunodeficiency virus; IF, intrathecal fraction; IgG, immunoglobulin G; IND, inflammatory neurological disease; NIND, non-inflammatory neurological disease; NND, no neurological disease; PIND, peripheral inflammatory neurological disease; Qalb, CSF/ serum albumin quotient; RBC, red blood cell; SC, symptomatic control; WBC, white blood cell
Fig 4Reproducibility of borderline OCB pattern.
Results in a subgroup of patients (n = 100) eligible for IEF replication experiments are shown. The 1st run of IEF shows the frequency of original OCB sub-pattern a, b and c, whereas the 2nd run of IEF shows the results of the replication experiments. Results are shown as percentage for (A) the whole patient group, (B) patients with IND, (C) PIND, (D) NIND, (E) SC and (F) NND. In panel (G) reproducibility of any borderline OCB pattern as well as of OCB sub-pattern are shown. Abbreviations: CSF+/S+, OCB in the CSF with identical bands in serum; CSF-/S-, no bands in CSF and serum; IEF, isoelectric focusing; IND, inflammatory neurological disease; NIND, non-inflammatory neurological disease; NND, no neurological disease; OCB, oligoclonal bands; PIND, peripheral inflammatory neurological disease; SC, symptomatic control.
Reports on the diagnostic value of oligoclonal bands.
| Publication | Type of | Immunoblotting/ | Number | CSF bands cut-off | Disease groups | Control groups–Categories | Control groups | Oligoclonal bands | |
|---|---|---|---|---|---|---|---|---|---|
| Sensitivity | Specificity | ||||||||
| Bayart 2018 | agarose | immunoblotting | 98 | ≥2 | MS | NIND | according to BioMS guidelines | 46/59 (78%) | 39/39 (100%) |
| Christiansen 2018 | agarose | immunofixation | 193 | ≥2 | MS | SC | SC: 66 patients with paresthesia, visual disturbances or vertigo, but no objective neurological deficits or MRI findings suggestive of MS (except for one RIS patient) | 79/96 (82%) | 91/97 (94%) |
| Gurtner 2018 | agarose | immunoblotting | 211 | ≥2 | MS | NIND | Patients with degenerative, non-inflammatory or peripheral neurological diseases and cancer | 63 | 121 |
| ≥3 | 59 | 127 | |||||||
| ≥4 | 58 | 130 | |||||||
| Dias-Carneiro 2016 | agarose | immunoblotting | 58 | ≥2 | MS | SC | SC: 15 patients with primary headaches | 23/32 (72%) | 25/26 (96%) |
| Hegen 2016 | PAGE | immunoblotting | 161 | ≥3 | n.a. | SC | according to BioMS guidelines | n.a. | 161/161 (100%) |
| Zeman 2015 | agarose | immunofixation | 122 | ≥2 | MS | NIND | NIND: 79 patients with migraine, PNP, vertebrogenic disease, radiculopathy, CNS tumor, vertigo, ischaemic stroke, IFNP, motor neuron disease, dementia. | 23/28 (82%) | 83/94 (88%) |
| Abraira 2011 | agarose | immunofixation | 81 | ≥2 | MS | NIND | Patients with stroke, NPH, ALS, paraneoplastic syndrome, intracranial hypertension, hereditary spastic paraplegia, epilepsy, Lewy body disease, migraine, pineal germ cell tumor | 49/52 (94%) | 28/29 (97%) |
| Gama 2009 | PAGE | immunoblotting | 109 | ≥2 | MS | SAS | - | 49 | 19 |
| Mygland 2007 | agarose | immunoblotting | 269 | ≥2 | MS | SC | SC: 142 patients with symptoms but without proven neurological cause | 13/14 (93%) | 245/255 (96%) |
| Sa 2005 | n.s. | immunoblotting | 242 | ≥2 | MS | NIND | The three most frequent diagnoses were ischaemic stroke, neurodegenerative disorder and spondilotic myelopathy | 58/69 (84%) | 167/173 (97%) |
| Bednarova 2005 | agarose | immunoblotting | 57 | ≥2 | MS | NIND | NIND: 8 patients with IFNP, vertebrogenic disorders, neurasthenia, polyneuropathy and neurodegenerative disorder. | 34 | 14 |
| Villar 2005 | agarose | immunoblotting | 466 | ≥2 | MS | NIND | 100 patients with NIND | 127/132 (96%) | 332 |
| Fortini 2003 | agarose | immunoblotting | 71 | ≥4 | MS | NIND | Patients with PNP, dementia, hereditary spastic paraparesis, epilepsy, spinocerebellar ataxia and transient ischemic attack | 18 | 48 |
| Haghighi 2000 | PAGE | immunoblotting | 97 | ≥2 | MS | Healthy | - | 45/47 (96%) | 48/50 (96%) |
| Marchetti 1999 | agarose | immunoblotting | 43 | ≥2 | MS | NIND | Patients with non-inflammatory CNS diseases | 20/21 (95%) | 20/22 (91%) |
| Cowdrey 1993 | PAGE | immunoblotting | 166 | ≥2 | MS | NIND | NIND: 133 Patients with headache, trauma, skeletal disorders degenerative and movement diseases, etc. | 21/22 (95%) | 142/144 (99%) |
| Öhman 1992 | agarose | immunoblotting | 323 | ≥2 | MS | NIND | Patients not to have any neurological disease affecting the CNS, e.g. tension headache, uncharacteristic dizziness, and mild psychoneurotic disorders. | 104/112 (93%) | 207/211 (98%) |
| ≥3 | MS | NIND | 100 | 207/211 (98%) | |||||
| McLean 1990 | agarose | immunoblotting | 692 | ≥3 | MS | NIND | Patients with headache; skeletal, vascular, degenerative, psychiatric, neoplastic, toxic, paroxysmal, metabolic, congenital or systemic disorders; neuromyopathie, trauma | 186/206 (90%) | 477/486 (98%) |
| Kostulas 1987 | agarose | immunoblotting | 955 | ≥2 | MS | NIND | Patients with IFNP, headache, epilepsy, cerebrovascular disease, dementia | 58/58 (100%) | 813/897 (91%) |
| Link 1983 | agarose | immunoblotting | 949 | ≥2 | MS | NIND | NIND: Patients with Parkinson’s disease, ALS, CNS tumor, PNP, intracranial haemorrhage, dementia, stroke, etc. | 41/43 (95%) | 780/902 (86%) |
Only studies were considered which detected OCB by means of IEF followed by IgG-specific immunofixation/ -blotting, specified a cut-off for CSF OCB used to calculate diagnostic sensitivity and specificity and provided patients’ clinical diagnoses allowing allocation to disease categories.
1 comprised patients predominantly with MS (n = 62), but also with CIS (n = 3) and RIS (n = 2).
2 comprised also patients with probable MS according to Poser criteria (n = 16).
3 The diagnoses of two control patients were not specified in the original publication.
§ Patients with non-inflammatory diseases were grouped to calculate diagnostic specificity of OCB.
* Number of OCB positive/ negative patients was not specified in the original publications, but calculated using % of OCB positive/ negative patients and total number of patients.
Abbreviations: ALS, amyotrophic lateral sclerosis; CIDP, chronic inflammatory demyelinating polyneuropathy; CIS, clinically isolated syndrome; CNS, central nervous system; GBS, Guillain-Barré syndrome; IFNP, idiopathic facial nerve palsy; IND, inflammatory neurological disease; MS, multiple sclerosis; n.a., not appropriate; NIND, non-inflammatory neurological disease; NPH, normal pressure hydrocephalus; n.s., not specified; OCB, oligoclonal bands; PAGE, polyacrylamide gel; PIND, peripheral inflammatory neurological disease; PNP, polyneuropathy; RIS, radiologically isolated syndrome; SAS, spinal anesthesia subjects; SC, symptomatic control, TBI, traumatic brain injury